Strategic portfolio expansion
In the past months, STADA was able to push ahead with the strategic portfolio expansion in important areas. In June 2018, STADA bought back the rights to the sunscreen Ladival and acquired the EMEA rights to the worldwide anti-dandruff brand Nizoral. In addition, STADA became the majority shareholder of BIOCEUTICALS Arzneimittel AG in August. This created an excellent basis for growth in OTC and biosimilars.
Three Pillar Strategy
STADA will be pursuing a three pillar strategy consisting of non-prescription OTC products, generics and specialty pharmaceuticals including biosimilars. The latter will focus on oncology, the central nervous system (CNS), diabetes and ophthalmology. Successful branded products are to become more internationalized in the future. As we already do, we will continue to offer a full portfolio in the generics segment.
In developed markets, STADA will work on closing gaps regarding product portfolios and pillars of the business model. Among the new markets, the Middle East will receive a lot of attention.
All of STADA's core processes will undergo a thorough revision. Generating Synergies on a group level and becoming more agile will be the main goals.